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Abstract
Multiple myeloma (MM) remains incurable with current therapy, indicating the need for continued
development of novel therapeutic agents. We evaluated the activity of a novel phenylbutyrate-
derived histone deacetylase inhibitor, AR-42, in primary human myeloma cells and cell lines.
AR-42 was cytotoxic to MM cells at a mean LC50 of 0.18 ± 0.06 μmol/l at 48 hr and induced
apoptosis with cleavage of caspases 8, 9 and 3, with cell death largely prevented by caspase
inhibition. AR-42 downregulated the expression of gp130 and inhibited activation of STAT3, with
minimal effects on the PI3K/Akt and MAPK pathways, indicating a predominant effect on the
gp130/STAT-3 pathway. AR-42 also inhibited interleukin (IL)-6-induced STAT3 activation,
which could not be overcome by exogenous IL-6. AR-42 also downregulated the expression of
STAT3-regulated targets, including Bcl-xL and cyclin D1. Overexpression of Bcl-xL by a
lentivirus construct partly protected against cell death induced by AR-42. The cyclin dependent
kinase inhibitors, p16 and p21, were also significantly induced by AR-42, which together with a
decrease in cyclin D1, resulted in G1 and G2 cell cycle arrest. In conclusion, AR-42 has potent
cytotoxicity against MM cells mainly through gp130/STAT-3 pathway. The results provide
rationale for clinical investigation of AR-42 in MM.
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Multiple myeloma (MM) is a clonal disorder of terminally differentiated B cells
characterized by accumulation of slowly proliferating plasma cells with an incidence of 3–4
per 100,000 in the United States.1 While advances in treatment, including the use of high-
dose chemotherapy and novel drugs such as thalidomide, lenalidomide and bortezomib have
improved patient outcomes,1 relapses invariably occur, indicating a need for continued
investigation of novel agents.
Intracellular signaling through the JAK/STAT, phosphatidylinositol 3-kinase (PI3K)/Akt
pathway, and Ras/Raf/MEK/extracellular signal-regulated kinase pathways contributes to
the survival, growth, proliferation and chemoresistance of MM cells.2,3 Constitutive
activation of STAT3 has been detected in MM as well as a number of other cancer types.4
Stat3 signaling participates in oncogenesis through the upregulation of genes encoding
apoptosis inhibitors (e.g., Bcl-xL, Mcl-1 and survivin) and cell cycle regulators (e.g., cyclin
D1 and c-Myc).5
Histone deacetylases (HDAC) are enzymes that determine the acetylation status of histones,
affecting chromatin structure and gene expression, and have emerged as a potential
therapeutic target. Initially, inhibitors of HDAC (HDACi) were developed as agents that
affect epigenetic processes by inducing histone hyperacetylation, leading to chromatin
remodeling and reactivated expression of transcriptionally repressed genes.6 However, in
addition to histone acetylation dependent-modulation of transcription, HDACi may also
exert their anticancer activity through action on nonhistone substrates with pivotal roles in
transformed cells.7,8 It is now known that HDACi can modulate a wide variety of cellular
functions, including transcriptional reactivation of dormant tumor suppressor genes as well
as modulating the expression of genes and proteins critical to cell proliferation, cell cycle
progression, apoptosis, cytoskeleton modifications and angiogenesis.6,7
The investigation of HDACi on MM cells has been limited to studies using sodium butyrate
and trichostatin A,9 valproic acid,10 LBH589,11 NVP-LAQ82412 and vorinostat.13–15
However, it is likely that significant differences exist between different HDACi with respect
to potency and cellular activity AR-42 (formerly known as (S)-HDAC-42) is a novel orally
bioavailable, phenylbutyrate-based HDAC inhibitor with a low-nanomolar IC50 for HDAC
inhibition and is currently planned for clinical evaluation as a therapeutic agent in cancer
(Arno Therapeutics, Parsippany, NJ). Significant antitumor activity, with higher potency
compared to vorinostat, has been reported with AR-42 against prostate cancer cells.8,16 In
PC-3 cells, AR-42 decreased the protein levels of phosphorylated (p)-Akt, Bcl-xL and
survivin.8 In this study, we evaluate the activity of AR-42 against MM cells and investigate
its potential mechanisms of action in this disease. AR-42 suppressed gp130 expression, and
both constitutive and inducible STAT3 activation. This correlated with downregulation of
STAT3 downstream cell survival and proliferation factors, Bcl-xL and cyclin D1, leading to
induction of apoptosis and G1 and G2 cell cycle arrest in MM cells.
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Material and Methods
Myeloma cells, culture conditions and reagents
The MM cell lines U266, H929, RPMI 8226, ARH-77 and IM-9 cell lines were purchased
from American Type Culture Collection (Manassas, VA). Cell lines were cultured in RPMI
1640 media (Gibco, Invitrogen Company, Grand Island, NY) and supplemented with 10%
heat-inactivated fetal bovine serum (FBS) (Gibco, Invitrogen Company, Grand Island, NY),
100 units/ml penicillin, 10 μg/ml streptomycin and 2 mM L-glutamine (Gibco). Primary
MM cells were purified from bone marrow aspirates obtained after informed consent from
patients at the time of diagnostic aspiration. Approval was obtained from the Institutional
Review Board of Indiana University. CD138+ cells from bone marrow aspirates were
separated using an LS+ column and a magnetic separator according to the manufacturer’s
instructions (Miltenyi Biotech, Auburn, CA) with resulting purity of >90% in all cases. Cell
viability as assessed by trypan blue exclusion was consistently >95%. CD138+ cells were
cultured in RPMI 1640 containing 10% FBS under the same condition as cell lines. The
caspase inhibitor, Q-VD-OPH, was purchased from Calbiochem, EMD Biosciences (La
Jolla, CA). (S)-HDAC-42 (AR-42) was synthesized in Dr. Ching-Shih Chen’s laboratory at
the Ohio State University, with purity exceeding 99% as shown by nuclear magnetic
resonance spectroscopy. The drug was diluted to an initial stock solution of 100 mmol/l in
dimethyl sulfoxide (DMSO), and aliquots were made of the stocks and stored at −80°C,
avoiding multiple freeze–thaw cycles.
Cell viability assay
Cell viability was analyzed by the CellTiter 96® AQueous Non-Radioactive Cell
Proliferation Assay (Promega, Madison, WI). Myeloma cells were plated in 96-well flat-
bottomed plates in a 100 μl total volume at a density of 2 × 104 cells per well. Triplicate
wells were treated with 10% FBS-supplemented RPMI 1640 media containing 0, 0.1, 0.25,
0.5, 0.75, 1.0, 2.5 and 5.0 μmol/l AR-42, or vehicle. The plates were incubated at 37°C in
5% CO2 for 24 or 48 hr. During the last 4 hr of the cell culture, the combined 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner
salt/electron coupling reagent phenazine methosulfate (MTS/PMS) solution was added into
each well of the 96-well assay plate containing 100 μl of cells in culture medium according
to the manufacturer’s instructions. Then the cells were incubated at 37°C for 4 hr and
absorbance was measured at 490 nm in a Victor 3 plate reader (PerkinElmer Life and
Analytical Sciences, Shelton, CT). Cell viability under drug treatment is reported as a
percentage of control.
Apoptosis assay
Following incubation with drug, cells were stained with annexin V–fluorescein
isothiocyanate (FITC) and propidium iodide (PI) according to the manufacturer’s directions
(BD Pharmingen, San Diego, CA) and analyzed by flow cytometry using a Beckman-
Coulter FC500 cytometer (Beckman-Coulter, Miami, FL). Fluorophores were excited at 488
nm, and fluorescence was measured using channel FL1 for annexin V-FITC, channel FL3
for PI. Data were analyzed with the CXP software package (Beckman-Coulter). At least
10,000 cells were counted for each treated sample. In experiments assessing caspase-
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dependent apoptosis, 20 μmol/l Q-VD-OPH was added 60 min before the addition of AR-42,
and flow cytometric analysis performed. In each case, at least three independent experiments
were preformed and the reported data represent the mean of the replicates.
Western blot analysis
Cells were treated with AR-42 for the indicated hours above, washed with ice-cold PBS and
resuspended in lysis buffer containing the phosphatase inhibitors sodium orthovanadate (1
mM) and microcystin LR (1 μmol/l) (both from Sigma, St. Louis, MO). Cell lysates were
collected after centrifugation at 13,000 rpm for 10 min. Equivalent amounts of proteins (50
μg) from each lysate were resolved in 4–20% sodium dodecyl sulfate–polyacrilamide gel
electrophoresis (SDS-PAGE). Protein was transferred to 0.2 μm nitrocellulose membranes
(Schleicher & Schuell, Keene, NH) and blots were probed with primary antibody specific
for the following proteins as appropriate at the indicated dilutions: p-Akt-Ser473 (1:200),
Akt (1:1,000), caspases 3 (1:1,000), 8 (1:500) and 9 (1:500), poly(ADP-ribose)polymerase
(PARP) (1:1,000), XIAP (1:1,000), Bax (1:500), p21 (1:500), p-STAT3 (Tyr705) (1:200),
STAT3 (1:200), BID (1:400); BIM (1:500) (Cell Signaling Technology, Beverly, MA), p16
(1:500), Bcl-2 (1:1,000), Bcl-xL (1;500); gp130 (1:200), glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (1:100,000), α-tubulin (1:2,000) (Santa Cruz Biotechnology,
Santa Cruz, CA), β-actin (1:2,000) (Novus Biologicals, Littleton, CO), acetyl-Histone H3
(Lys9) (1:1,000) (Millipore Corporation, Billerica, MA) and FLIP (1:1,000) (AXXORA,
LLC, San Diego, CA). Following incubation with antibody, the proteins were detected with
chemiluminescent substrate (SuperSignal, Pierce, Rockford, IL). Protein bands were
quantified by integration of the chemiluminescence signals on Quantity One (Bio-Rad
Laboratories, Hercules, CA).
Overexpression of Bcl-xL in MM cell lines
The pCL6IEGwo vector control or a pCL6IEGwo-Bcl-xL lentiviral construct were
transduced into U266 cells to generate pCL6IEGwo control and pCL6IEGwo-Bcl-xL cells.
The pCL1IEGwo-Bcl-xL construct was made by cloning the full length Bcl-xL cDNA,
generated by PCR, into the pCL6IEGwo vector. Western blot analysis confirmed that Bcl-
xL was over-expressed in pCL6IEGwo-Bcl-xL cells.
Overexpression of c-FLIP (L) in H929
The pCL1IEG vector control or a pCL1IEG-cFLIP lentiviral construct were transduced into
H929 cells to generate H929-pCL1IEG and H929-cFLIP cells. The pCL1IEG-cFLIP
construct was made by cloning the full length cFLIP cDNA, generated by PCR, into the
pCL1IEG vector. Western blot analysis confirmed that c-FLIP(L) was overexpressed in
H929-c-FLIP cells.
Results
AR-42 is a potent antimyeloma agent and induces apoptosis in MM cells
The in vitro activity of AR-42 against MM cells was evaluated after 24–96 hr of exposure to
drug. Cells were grown in the absence or the presence of different concentrations (0.1, 0.25,
0.5, 0.75, 1.0, 1.5, 2.5 and 5 μmol/l) of AR-42, and cytotoxicity was measured by the MTS
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assay. AR-42 effectively induced cell death in all cell lines tested (Fig. 1a). The LC50 of
AR-42 after 48 hr of exposure to the drug was 0.25 ± 0.01, 0.15 ± 0.02, 0.25 ± 0.07, 0.11 ±
0.01 and 0.17 ± 0.02 μmol/l, respectively, for U266, H929, RPMI 8226, ARH-77 and IM-9
cells. The cytotoxicity of AR-42 was confirmed in primary MM cells with LC50 of 0.17 ±
0.03 μmol/l at 48 hr. Extending drug exposure to 72 and 96 hr resulted in additional
cytotoxicity, indicating that AR-42 also induced the cell death in a time-dependent manner
(Fig. 1b; 72 hr result not shown).
To determine whether MM cell death induced by AR-42 involves apoptosis, flow cytometric
analysis with annexin V–PI staining was performed. AR-42 induced apoptosis in a time- and
dose-dependent manner in all cell lines tested in the dose range of 0.25–2.5 μmol/l. Figure
1c is a representative example of apoptosis of U266 cell line treated with 0.5 μmol/l of
AR-42 at 24 and 48 hr; strong apoptosis was also observed at the other concentrations (data
not shown).
AR-42 induces cell death in a caspase-dependent manner by cleavage of caspases 3, 8
and 9
The mechanisms of cell death by different HDACi may vary in different cancer cell
types.17–22 We, therefore, explored the effect of AR-42 on caspase-dependent apoptotic
pathways. AR-42 induced cleavage of caspases 3, 8 and 9, as well as PARP, in a dose-
dependent manner after 24-hr incubation with the drug (Fig. 2a). To determine the
dependence of AR-42-induced apoptosis on the caspase pathway, we assessed the ability of
the pancaspase inhibitor, Q-VD-OPH to protect against cell death. As shown in Figure 2b,
Q-VD-OPH reduces AR-42-induced cell death as determined by annexin V-PI staining and
the effect is only partial. We next examined whether Q-VD-OPH was actually inhibiting
AR-42 activation of caspase-3 as measured by processing of the proform and downstream
cleavage of PARP that is characteristic of caspase-dependent apoptosis. U266 cells were
exposed to AR-42 in the presence or absence of Q-VD-OPH and cell lysates made (n = 3).
As shown in Figure 2b, Q-VD-OPH greatly diminished processing of cleavage of PARP and
caspase-3 as well as preventing cell death. These data together demonstrate that while
apoptosis is induced by AR-42 mainly through caspase-dependent mechanisms, noncaspase
dependent pathways may also operate.
AR-42 induces histone acetylation in MM cells
To verify whether AR-42 induced hyperacetylation of histones, MM cells were treated with
AR-42 at different concentrations and time points and histone H3 acetylation analyzed by
Western blotting on whole cell lysates. As shown in Figures 2c and 2d for U266 cells as a
representative example, AR-42 induced histone H3 acetylation in a time- and dose-
dependent manner as early as 1 hr, and reaching maximal effect by 24 hr.
AR-42 decreases gp130 subunit of the interleukin-6 receptor complex levels and inhibits
constitutive and inducible STAT3 phosphorylation in MM cells
The proliferation and survival of MM cells are dependent, in large part, on interleukin (IL)-6
and IL-6 receptor stimulation through autocrine and paracrine loops.23,24 IL-6 stimulates
three major survival pathways, including the JAK2/STAT3, the Ras/Raf/MEK/MAPK and
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the PI3K/AKT pathways.25–28 Signaling through the IL-6 receptor is via the gp130 signal
transduction subunit, which following dimerization leads to phosphorylation of STAT3 at
tyrosine residue 705 leads to activation of the JAK2/STAT3 pathway.29 In the human
myeloma cell line U266, STAT3 is constitutively activated through an IL-6 autocrine loop.
Inhibition of the constitutive STAT3 pathway induces the cells into apoptosis.4
We first evaluated the effect of AR-42 on the expression of p-STAT3 and gp130 in U266
cells. Figure 3a shows that treatment of U266 cells with low concentrations of AR-42 for 24
hr leads to a significant reduction in gp130 expression as well as tyrosine-phosphorylated
STAT3 although total STAT3 was unaffected. While AR-42 reduced p-STAT3 as early as
1–5 hr after drug exposure, gp130 was not significantly reduced at these early time points
(Fig. 3b). On the other hand, AR-42 caused only a marginal decrease in p-MEK levels and
no significant change in Akt and p-Akt expression (Fig. 3a). Next, we examined whether
AR-42 could inhibit IL-6-induced STAT3 phosphorylation in H929 cell lines. H929 cells
were pretreated with AR-42 for 24 hr and then stimulated with IL-6 for 15 min. As shown in
Figure 3c, IL-6 induced STAT3 phosphorylation was reduced by AR-42. Importantly,
exogenous IL-6 did not protect MM cells from AR-42-induced cytotoxicity despite its
stimulatory activity on cell growth in H929 and U266 cells not exposed to drug (Fig. 3d;
results for U266 not shown). The results indicate that gp130/STAT3 pathway is likely an
important target of AR-42 in MM cells.
AR-42 downregulates Bcl-xL expression, and overexpression of Bcl-xL partially protects
against AR-42-mediated cytotoxicity of MM cells
The apoptosis inhibitor, Bcl-xL, is one of the key downstream targets of STAT3 in MM
cells, considered important for myeloma cell survival and drug resistance.4 As shown in
Figure 4a, AR-42 treatment strongly downregulated Bcl-xL expression in U266 cells.
Furthermore, overexpression of Bcl-xL using lentivirus gene transduction partially protected
against AR-42-induced cell death (Figs. 4b and 4c), indicating that reduction in Bcl-xL may
contribute an important role in AR-42-induced apoptosis in MM cells.
AR-42 downregulates c-FLIP expression and only minor effects on other anti- or
proapoptotic proteins
We also evaluated the relative expression levels of other pro-and antiapoptotic proteins,
which have been shown to be important for the survival of MM cell and their resistance to
chemotherapeutic agents.30 As shown in a representative experiment in Figure 4a, Bcl-2,
Bax, BAK, BID and BIM showed no significant change in expression in MM cells
following treatment with AR-42. Similarly, there was minimal if any significant change in
the expression of proteins of the inhibitor of apoptosis (IAP) family, including survivin and
the X-linked inhibitor of apoptosis (XIAP) following exposure to AR-42 (Fig. 4a).
As AR-42 induced-apoptosis was associated with caspase 8 activation, we investigated the
expression of cellular FLICE-like inhibitory protein (c-FLIP) following drug exposure. c-
FLIP is an inhibitor of death receptor-mediated apoptosis and exists as a family of
alternatively spliced variants, including long (c-FLIP (L)) and short (c-FLIP (S)) splice
variants in human cells.31 Upregulation of c-FLIP in MM cells by bone marrow stroma has
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been reported to mediate resistance to Apo2 ligand/TRAIL induced apoptosis.32 As shown
in Figure 4a, AR-42 treatment resulted in a significant reduction of c-FLIP (L) and c-FLIP
(S) in U266 (Fig. 4a) and H929 cells (data not shown). Despite this change, however,
overexpression of c-FLIP (L) using lentivirus gene transfer failed to protect against drug-
induced cell death (Fig. 4d), indicating that reduction in c-FLIP is not likely a dominant
mechanism in AR-42-induced apoptosis in MM cells.
AR-42 downregulates cyclin D1, increases p21 and p16 expression and induces G1 and G2
cell cycle arrest in MM cells
As the cell cycle promoter cyclin D1 is another key downstream factor of STAT3,5 we
investigated the effect of AR-42 on its expression. As shown in Figures 5a and 5b, a
reduction in cyclin D1 was observed as early as 5 hr after treatment but was completed
reduced by 0.25–0.75 μmol/l of AR-42 after 24 hr, although cyclins A and B1 were
unaffected. The promoter of p21 gene is regulated by histone acetylation status and
induction of p21 is a hallmark of HDAC inhibitors.33 As increased expression of p21 results
in inhibition of proliferation, we examined the effect of AR-42 on its expression and that of
p16, another cell cycle inhibitor that has been shown to be transcriptionally silenced in
MM.34 Expression of both p21 and p16 proteins was induced by AR-42 as early as 5 hr after
treatment but was quite profound at 24 hr (Figs. 5a and 5b). Consistent with the above
findings, cell cycle analysis data showed that AR-42 induces G1 and G2 cell cycle arrest in
MM cells (Fig. 5c).
Discussion
HDAC have recently been investigated as potential targets in the treatment of MM.10–14
However, while a recent clinical trial of vorinostat in MM has reported only modest
efficacy,15 HDACi differ in their spectrum of cellular activity and those currently available
clinically, such as valproic acid and vorinostat, suffer from low potency and/or poor oral
bioavailability. We, therefore, investigated the effects of a novel phenylbutyrate derived-
HDACi, AR-42, in MM cell lines and primary myeloma cells. We show that AR-42 has a
significant inhibitory effect on IL-6 receptor signaling, downregulating the signaling
transduction subunit gp130 and blocking STAT3 phosphorylation, thereby inducing
resistance to IL-6 stimulation. AR-42 also decreases the expression and cyclin D1 and Bcl-
xL, two major downstream targets of STAT3, and overexpression of Bcl-xL partly protects
against AR-2-induced myeloma cell death. Finally, AR-42 upregulates the cell cycle
inhibitors p21 and p16 and inhibits cell cycle progression.
The mechanisms of HDACi-induced cytotoxicity may vary depending on the class of
HDAC being inhibited and the downstream targets of HDAC in different cancer cells. Our
results in MM show that AR-42-induced apoptosis is associated with cleavage of caspases 8,
9 and 3, and PARP cleavage, suggesting that the drug activates both the extrinsic and
intrinsic apoptotic pathways. Further, AR-42-induced apoptosis is in large part dependent on
caspase activation. The dependence on caspase activation for induction of apoptosis by
AR-42 appears to differ from other HDACi tested in MM. While LBH589 also induced
caspase and PARP cleavage, caspase inhibition had only modestly protected against cell
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death,11 suggesting other mechanisms likely dominate. On the other hand, vorinostat-
induced cytotoxicity in MM cells was not associated with activation of caspases 8, 9 and 3,
but induced cell death in a calpain-dependent manner.14 This difference between vorinostat
and AR-42 was also observed in prostate cancer cells.8 Therefore, the mechanisms of cell
death by distinct HDACi are specific.
In MM cells, AR-42 also modulates the expression of the antiapoptotic proteins. Of the
Bcl-2 family members, only Bcl-xL expression was significantly reduced, while other
family members, including Bcl-2, BAX and BAK remain unaffected. Bcl-xL has been found
to play an important role in the regulation of apoptosis by at least two different mechanisms,
including the interaction with proapoptotic proteins of the Bcl-2 family (such as BAX) and
with non-Bcl-2 family proteins, such as Apaf-1, thereby inhibiting Apaf-1-dependent
caspase-9 activation, and by a direct pore-forming effect on the outer membrane of
mitochondria.35,36 The changes in Bcl-2 family members with AR-42 differ from those
previously reported with vorinostat. While a change in Bcl-xL expression has not been
reported with vorinostat, treatment of MM cells with the latter drug resulted in upregulation
of the proapoptotic proteins Bim, Bak and Bax,37 although these remained unchanged with
AR-42. Further, unlike the effect of vorinostat on MM,14 we did not observe cleavage of Bid
(Fig. 4a). Together, these results highlight the differences between the actions of different
HDACi and suggest that the effect of AR-42 on Bcl-2 family members in MM is
predominantly on Bcl-xL, as also previously reported in prostate cancer cells.8 More
importantly, overexpression of Bcl-xL partially protects against AR-42-mediated
cytotoxicity suggesting that reduction in Bcl-xL plays an important role in AR-42-induced
apoptosis in MM cells. In addition to the effect on Bcl-xL, AR-42 also appeared to reduce
the expression of c-FLIP. c-FLIP has been reported to regulate apoptosis by inhibiting
caspase 8 activation.38 Moreover, c-FLIP is overexpressed in MM and direct silencing of c-
FLIP using siRNA has been shown to inhibit the proliferation of MM cells.39,40 However,
although AR-42 downregulated c-FLIP in MM cells and may have accounted for facilitation
of caspase 8 cleavage, we could not demonstrate that this is a dominant mechanism of cell
death as constitutive expression of c-FLIP failed to provide protection against AR-42-
induced apoptosis.
Interference with progression through the cell cycle is an important mechanism observed
with HDACi. Both vorinostat and LBH589 have been shown to induce G1 cell cycle arrest
in MM cells and other cancer cell types.11,14 Similar to these HDACi, AR-42 also induced
G1 arrest, although an additional effect was also seen on the G2 phase of the cell cycle.
AR-42 induced significant expression of the cyclin dependent kinase (CDK) inhibitors p16
and p21. The induction of p16 expression has not been previously reported for other HDACi
in MM, although has been observed in other cancer cell types with valproic acid.41,42 On the
other hand, induction of p21 expression has previously been reported in MM cells treated
with almost all other HDACi.43,44 p16, inhibits G1 CDKs specifically, while p21, inhibits
CDK in all phases of the cell cycle45 and may explain the effect of AR-42 on inhibiting
progression also through G2. Both p16 and p21 block the formation of cyclin-CDK
complexes, allowing Rb to become activated and halting the cell cycle. In addition to
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inducing p16 and p21, AR-42 also downregulates cyclin D1 in MM cells contributing to
arrest in the G1 phase, an effect common to other HDACi.
IL-6 plays an important role in the growth and survival of MM cells,23,46 and the signal
transduction subunit gp130 is the central player in receptor complexes formed by IL-6-type
cytokines.29 Our results indicate that AR-42 exerts an important inhibitory effect on the IL-6
signal transduction pathway by downregulating the expression of gp130 and inhibiting
constitutive and inducible STAT3 phosphorylation. While the mechanism by which gp130 is
down regulated remains uncertain, the relatively late time course at which this effect is
observed (24 hr) likely indicates that this occurs at the transcription level rather than
degradation of the receptor subunit.47,48 Furthermore, inhibition of STAT3 phosphorylation
may further contribute to this effect on gp130 as previously reported.47 However, minimal if
any changes were observed in the expression of p-Akt or p-MEK, suggesting that the effect
of the drug is mainly through the gp130/STAT3 pathway. Another HDACi, atiprimod, has
also been found to have a negative effect on STAT3 phosphorylation in MM cells.49 STAT3
directly and indirectly upregulates the expression of genes that are required for uncontrolled
proliferation and survival of tumor cells, including Bcl-xL and cyclin D1.50 Indeed,
inhibition of STAT3 leads to a decrease in Bcl-xL expression and promotes the induction of
apoptosis in U266.4 In our study, the reduction of Bcl-xL and cyclin D1 induced by AR-42
may be, at least in part, through an inhibitory effect on the gp130/STAT3 pathway.
Importantly, AR-42 overcomes the growth and survival promoting effect of IL-6.
In conclusion, our results show that the novel orally bioavailable HDACi, AR-42, has potent
activity against MM cells with overlapping, but unique, mechanisms of action compared to
other HDACi previously reported. Its ability to target mainly the gp130/STAT3 cellular
pathway and downstream antiapoptotic and cell cycle proteins at nanomolar concentrations
that are likely achievable in vivo,9 suggest its viability as part of the therapeutic
armamentarium for MM. Our results provide preclinical rationale for clinical development
of AR-42 for MM.
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Abbreviations
CDK cycle dependent kinase
c-FLIP cellular FLICE-like inhibtor protein
HDAC histone deacetylase
HDACi HDAC inhibitor
IAP inhibitor of apoptosis
IL-6 interleukin-6
MM multiple myeloma
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pH3 phosphorylated histone 3
PI3K phosphatidylinositol 3-kinase
X-IAP X-linked inhibitor of apoptosis
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Figure 1.
AR-42 is cytotoxic to MM cells in a dose- and time-dependent manner. (a) MTS assay
showing percentage of viable MM cells treated with 0, 0.1, 0.25, 0.5, 0.75, 1.0, 2.5 and 5
μmol/l of AR-42 for 48 hr. Results expressed as mean with standard error of three
independent experiments in cell lines, and as mean with standard error of two different
patient primary MM samples. (b) U266 and H929 MM cells were treated with AR-42 or
vehicle for 96 hr, and proliferation measured using MTS assay. (c) Flow cytometry results
of annexin V-PI staining of U266 cells after exposure to DMSO or AR-42 (0.5 μmol/l) for
24 or 48 hr. An increase in early apoptotic (A+P−) cells following treatment with AR-42 is
shown.
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Figure 2.
AR-42 induces cell death in a caspase-dependent manner and induces hyperacetylation of
histone H3. (a) Caspase activation and PARP cleavage following treatment with AR-42.
Lysates from MM cells treated with 0, 0.25, 0.5 and 0.75 μmol/l AR-42 for 24 hr were
probed for caspase-3, caspase-8, caspase-9 or PARP by immunoblot. (b) Caspase inhibition
protects against AR-42-induced cell death. MM cells were incubated in 0.05% DMSO, 0.5
μmol/l AR-42 or a combination of Q-VD-OPH (20 μmol/l) and 0.5 μmol/l AR-42, followed
annexin V-PI staining 48 hr later. Lysates from treated cells were probed for caspase 3 or
PARP by immunoblot. Immunoblot is representative of three independent experiments. (c)
Immunoblot of cell lysates showing a dose dependent increase in acetylated histone H3 with
AR-42 treatment in U266 at 24 and 48 hr. (d) AR-42 (0.75 μmol/l) induced a time dependent
increase in histone H3 acetylation in U266 cell lines. Histone H3 acetylation was induced as
early as 1 hr and reached a maximum level at 24 hr.
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Figure 3.
AR-42 downregulates gp130 and reduces constitutive and inducible p-STAT3 in MM cells.
(a) U266 cells were treated for 24 hr with or without AR-42 and analyzed for the indicated
protein by immunoblotting. (b) AR-42 reduced p-STAT3 as early as 1–5 hr in U266 cells,
although gp130 was minimally altered at these early time points. U266 cells were cultured in
10% FBS RPMI 1640 media with DMSO (0.05%) or AR-42 (0.75 μmol/l). (c) AR-42
reduces IL-6-induced phosphorylation of STAT3 in H929. H929 cells were cultured in
serum-free RPMI 1640 media for 22 hr followed by culture in serum-free RPMI 1640 media
with 0.05% DMSO (control) or AR-42 (0.75 μmol/l) for 24 hr. Cells were then cultured with
or without 10 ng/ml recombinant human IL-6 for 15 min and lysates made. (d) Exogenous
IL-6 does not protect MM cells from the inhibitory effect of AR-42. H929 cells were treated
with AR-42 (0.75 μmol/l) in the presence or absence of recombinant human IL-6 (10 ng/ml)
for 24 hr and then analyzed for proliferation by MTS assay (results represent mean of three
independent experiments). AR-42 also reduced IL-6 induced p-STAT3 expression in H929
as shown in Western blot.
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Figure 4.
AR-42 downregulates Bcl-xL and c-FLIP. (a) Expression of Bcl-2 family proteins, c-FLIP,
IAP family proteins, survivin and XIAP in U266 cells following 24-hr exposure to AR-42
(Western blot representative of three independent experiments). (b, c) Overexpression of
Bcl-xL partially protected against AR-42-mediated cytotoxicity in U266 cells. (b) Viability
of U266 cells transduced with Bcl-xL and empty pCL6IEGwo vector after treatment with
AR-42 for 72 hr (data is representative of three independent experiments). (c) Expression of
Bcl-xL in stably transduced U266 cells confirming overexpression. U266 control, U266 cell
lines transduced with empty pCL6IEGwo vector; U266-Bcl-xL: U266 transduced cells with
overexpression of Bcl-xL. (d) Overexpression of c-FLIP (L) fails to protect against AR-42-
induced cell death in H929 cells. Top, overexpression of c-FLIP (L) in stably transduced
H929 cells. Bottom, viability of H929 cells transduced with c-FLIP (L) and empty pCL1
vector after treatment with AR-42 for 48 hr (results are the mean of three independent
experiments). H929-pCL1, H929 cells transduced with empty pCL1IEG vector; H929-FLIP-
L: H929 transduced cells with overexpression of c-FLIP (L).
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Figure 5.
Effect of AR-42 on cell cycle proteins and cell cycle progression. (a) AR-42 induces
expression of p16 and p21 and reduces expression of cyclin D1. U266 cells were treated
with 0.05% DMSO or AR-42 at the shown concentrations for 24 hr. Lysates were then
prepared immediately and analyzed by Western blot for cyclin D1, p21, p16, cyclin A and
cyclin B. (b) Early change in cyclin D1, p16 and p21 with 0.05% DMSO or 0.75 μmol/l
AR-42 in U266 cells. As noted, a reduction in cyclin D1 and induction of p16 and p21 are
noted as early as 5 hr after treatment with AR-42. (c) Cell cycle analysis in AR-42-treated
U266 cells showing arrest in G1 and G2 phases. U266 cells were incubated with 0.05%
DMSO or with 0.25, 0.5 or 0.75 μmol/l AR-42 for 24 hr. The percentage of cells in each
phase of the cell cycle is presented as mean ± SD from three independent experiments.
Following treatment with AR-42 for 24 hr, there was a significant increase in the percentage
of cells in G0/G1 or G2/M relative to DMSO control (p values: ap = 0.0035; bp = 0.0198; cp
= 0.0289; dp = 0.0151; ep = 0.0113; fp = 0.0134; Student t-tests).
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